Hetrombopag Olamine

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chemotherapy-Induced Thrombocytopenia

Conditions

Chemotherapy-Induced Thrombocytopenia

Trial Timeline

Jul 1, 2023 → Jan 1, 2027

NCT ID

NCT05944211

About Hetrombopag Olamine

Hetrombopag Olamine is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Chemotherapy-Induced Thrombocytopenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05944211. Target conditions include Chemotherapy-Induced Thrombocytopenia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05944211	Phase 2	Recruiting	Jul 1, 2023	Jan 1, 2027	Chemotherapy-Induced Thrombocytopenia
NCT03977805	Phase 1	Completed	May 25, 2019	Jun 13, 2019	Healthy
NCT03603132	Phase 1	Completed	Jul 14, 2018	Aug 17, 2018	Immune Thrombocytopenia
NCT03557099	Phase 1/2	Completed	Jun 20, 2018	Jul 23, 2020	Severe Aplastic Anemia
NCT02614846	Phase 1	UNKNOWN	Aug 1, 2015	—	Chronic Idiopathic Thrombocytopenic Purpura
NCT02403440	Phase 1	UNKNOWN	Apr 1, 2014	—	Purpura, Thrombocytopenic, Idiopathic
NCT02409394	Phase 1	Completed	Mar 1, 2014	Apr 1, 2014	Healthy

Competing Products

20 competing products in Chemotherapy-Induced Thrombocytopenia

See all competitors

Product	Company	Stage	Hype Score
SON-080	Sonnet BioTherapeutics	Phase 1/2	36
Granisetron	Kyowa Kirin	Phase 3	77
ONO-7746	Ono Pharmaceutical	Phase 1	33
ONO-2910 + Placebo	Ono Pharmaceutical	Phase 2	52
PROCRIT 40,000 IU QW + Placebo	Johnson & Johnson	Phase 2	52
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag + Hetrombopag plus Placebo + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag + Matching placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue Therapy	Merck	Phase 3	77
Fosaprepitant	Merck	Phase 2	52
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonist	Merck	Phase 3	77
Fosaprepitant + Dexamethasone + 5HT3	Merck	Phase 2	52
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasone	Merck	Phase 3	77
aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified)	Merck	Phase 3	77
EMEND	Merck	Pre-clinical	23
Fosaprepitant Dimeglumine + 5-HT3 antagonist + Dexamethasone	Merck	Approved	85
ondansetron clinical trial formulation + ondansetron marketed formulation	Merck	Phase 1	33
Aprepitant + Palonosetron + Dexamethasone	Merck	Phase 2	52
Fosaprepitant 150 mg + Aprepitant 165 mg + Aprepitant 250 mg + Dexamethasone (12-8-16-16 mg) + Dexamethasone (12-8-8-16 mg) + Ondansetron + MK0999	Merck	Phase 1	33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved